Please note: on 13 May 2013 an updated version of the interactive spreadsheet was uploaded to reflect an error in the data presented relating to Table 2.1: Defined Daily Dose per 100,000 of the population by CCG (Clinical Commissioning Group) area. The original data presented was Net Ingredient Cost, but was described as Defined Daily Dose. The title of this data has now been changed to Net Ingredient Cost and an additional table has been provided showing Defined Daily Doses.
Whilst the actual figures for each CCG for Defined Daily Dose compared to the Net Ingredient Cost are very different, the relativities between organisations are similar in either measure for Bupropion Hydrochloride, Celecoxib, Orlistat and Tiagabine. The relativities have changed to different degrees for the other drugs presented, possibly due the availability of different presentations and varying use of generics.
On 24th January 2013 an updated version of the interactive spreadsheet was uploaded to correct an error in the text relating to Osteoporosis in Part 1 of the interactive worksheet as the original text referred to this as Statins data. The error concerned the text and not the data, which is unchanged. The figure presented for Verteporfin (England level) has also been corrected; this was 177 milligrams per 100,000 FCE bed days and should have been 30 milligrams per 100,000 FCE bed days.
The National Institute for Health and Clinical Excellence (NICE) technology appraisal process assesses the clinical and cost effectiveness of new and existing medicines and treatments, and provides guidance on their use by the NHS.
The Innovation Health and Wealth paper published by the Department of Health in December 2011, set out plans to support development and adoption of innovation in the NHS. One of the actions in this paper is to drive compliance with technology appraisals by the publication of information relating to levels of compliance and variation at a local level.
The Health and Social Care Information Centre was requested to develop and publish a scorecard on behalf of the Department of Health (DH) and the NHS Commissioning Board (NHS CB). There is no central collection of data to directly support this nor is data on the number of patients being treated available centrally. Therefore this is an experimental publication, which presents available data from a range of sources and requests comments and suggestions from users to support future development of appropriate datasets.
The data is presented in the form of an interactive spread-sheet which uses macros to allow users to identify the organisations and interventions they wish to explore. The data is also presented in tables and charts to show variation. An accompanying report describes the data, the sources and its limitations. This is supported by additional information in an FAQ format.
This publication is also known as the Innovation Scorecard.